Vuno Inc. announced that it has entered into a memorandum of understanding with DongKoo Bio&Pharma Co., Ltd. (KOSDAQ:A006620) and received KRW 3,000,000,000 in a round of funding on May 19, 2020. The company is pushing for an initial public offering within 2020.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31,050 KRW | +1.14% | +9.33% | -26.07% |
26/03 | Vuno Inc. announced that it has received KRW 10.4 billion in funding | CI |
21/03 | Vuno Inc. announced that it expects to receive KRW 10.4 billion in funding | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.07% | 31Cr | |
+18.89% | 393.96Cr | |
+2.59% | 307.34Cr | |
-33.04% | 161.81Cr | |
-26.18% | 61Cr | |
-12.88% | 34Cr | |
-10.90% | 21Cr | |
-2.07% | 20Cr | |
-19.35% | 14Cr | |
+2.90% | 14Cr |
- Stock Market
- Equities
- A338220 Stock
- News Vuno Inc.
- Vuno Inc. announced that it has received KRW 3 billion in funding from DongKoo Bio&Pharma Co., Ltd.